VISTA Carrier Screening Test in Pakistan at Chughtai Lab

VISTA Carrier Screening Test (hongkong) at Chughtai Lab

The VISTA Carrier Screening Test (hongkong) at Chughtai Lab is a highly advanced, comprehensive molecular diagnostic test designed to identify whether individuals or couples carry genetic mutations that could be passed on to their children. This test utilizes state-of-the-art Next-Generation Sequencing (NGS) technology to analyze genomic DNA for pathogenic and likely pathogenic variants associated with autosomal recessive and X-linked genetic disorders. For prospective parents, understanding their carrier status is a critical step in family planning, helping to prevent the transmission of severe, life-limiting, or debilitating hereditary conditions to their offspring.

Genetic carriers are typically asymptomatic individuals who possess one mutated copy of a gene and one normal copy. Because they do not exhibit any symptoms of the disease, most carriers are entirely unaware of their genetic status until they have an affected child. When two carriers of the same autosomal recessive condition conceive, there is a 25% chance with each pregnancy that the child will inherit both mutated genes and be born with the disorder. For X-linked conditions, a female carrier has a 50% chance of passing the mutated gene to her sons, who will be affected, and a 50% chance of passing it to her daughters, who will become carriers. The VISTA Carrier Screening Test provides crucial genomic insights to mitigate these risks, offering couples clear, actionable information before or during early pregnancy.

At Chughtai Lab, Pakistan's leading diagnostic network, this test is performed under the supervision of expert molecular pathologists and geneticists. The laboratory utilizes high-throughput sequencing platforms to screen a broad panel of clinically relevant genes, ensuring high analytical sensitivity and specificity. By identifying potential genetic risks early, Chughtai Lab empowers families and healthcare providers to make informed reproductive decisions, which may include pre-implantation genetic testing (PGT), prenatal diagnosis, or preparing for specialized postnatal medical care.

Clinical Procedure: What to Expect

Patient Preparation

Proper preparation is essential to ensure sample integrity and accurate molecular analysis. Patients undergoing the VISTA Carrier Screening Test at Chughtai Lab should observe the following guidelines:

• No Fasting Required: Unlike routine biochemistry profiles, fasting is not required for this genetic test. Patients may eat and drink normally prior to sample collection.
• Clinical Documentation: Patients must provide a detailed family medical history, particularly any history of congenital disorders, developmental delays, unexplained infant deaths, or known genetic conditions.
• Informed Consent: Because this is a highly complex genetic test, patients are required to sign an informed consent form. This document explains the scope, limitations, and potential implications of the genetic findings.
• Genetic Counseling: It is highly recommended that couples undergo pre-test genetic counseling to fully understand what the test screens for and how the results may impact their reproductive choices.
• Medication Reporting: Inform the laboratory staff of any recent blood transfusions, bone marrow transplants, or ongoing immunosuppressive therapies, as these can interfere with DNA extraction and sequencing accuracy.

During the Procedure

The collection and processing of the sample for the VISTA Carrier Screening Test follow strict clinical protocols to prevent contamination and preserve genomic DNA:

• Sample Collection: A trained phlebotomist at Chughtai Lab will perform a standard venipuncture to collect a peripheral blood sample. Typically, 3 to 5 mL of blood is drawn into an EDTA (lavender top) tube.
• Aseptic Technique: The venipuncture site, usually the median cubital vein in the arm, is thoroughly cleansed with an antiseptic swab to prevent bacterial contamination of the sample.
• Sample Labeling and Transport: The collection tube is immediately labeled with the patient's unique identification details and barcoded. It is then transported under temperature-controlled conditions to the specialized molecular genetics department.
• DNA Extraction: In the laboratory, genomic DNA is extracted from the white blood cells. The quantity and purity of the extracted DNA are verified using spectrophotometric or fluorometric assays.
• Next-Generation Sequencing (NGS): The purified DNA undergoes library preparation and target enrichment for the specific gene panels. It is then sequenced on high-throughput NGS platforms, which read millions of DNA fragments simultaneously.
• Bioinformatics Analysis: Advanced bioinformatics pipelines compare the patient's genetic sequence against standard reference genomes to identify any mutations, insertions, deletions, or copy number variations.
• Duration and Comfort: The blood draw itself takes less than five minutes and involves minimal discomfort, similar to a standard blood test. The subsequent laboratory analysis is highly complex and takes several weeks to complete.

When is a VISTA Carrier Screening Test Performed?

Pre-conception Planning for Couples

The ideal time to perform the VISTA Carrier Screening Test is before pregnancy. When a couple undergoes screening prior to conception, they have the widest range of reproductive options available if both partners are found to be carriers of the same genetic disorder. This proactive approach allows couples to explore options such as in vitro fertilization (IVF) with pre-implantation genetic testing for monogenic disorders (PGT-M) to select unaffected embryos, use of donor gametes, or adoption.

Consanguineous Marriages (Family Marriages)

In regions like Pakistan, where consanguineous marriages (marriages between close relatives, such as first cousins) are culturally common, the risk of autosomal recessive genetic disorders is significantly elevated. Because close relatives share a higher percentage of their DNA, they are much more likely to carry the exact same recessive genetic mutations inherited from a common ancestor. Performing the VISTA Carrier Screening Test in consanguineous couples is highly recommended to identify these shared genetic risks before starting a family.

Family History of Inherited Genetic Disorders

If an individual has a family history of a specific genetic condition, such as Beta-thalassemia, Spinal Muscular Atrophy, or Cystic Fibrosis, their risk of being a carrier is substantially higher than that of the general population. Physicians recommend the VISTA Carrier Screening Test to determine if the individual has inherited the familial mutation. If they are a carrier, their partner is also screened to assess the cumulative risk to future pregnancies.

History of Recurrent Pregnancy Loss or Stillbirth

Couples who have experienced multiple unexplained miscarriages, recurrent pregnancy loss, or stillbirths are often advised to undergo comprehensive carrier screening. Many severe genetic mutations are lethal in homozygous states, leading to early embryonic death or late-term fetal demise. Identifying these lethal recessive mutations in the parents helps explain the underlying cause of recurrent pregnancy losses and guides future obstetric management.

Assisted Reproductive Technology (ART) and IVF Planning

Fertility clinics routinely recommend carrier screening for couples undergoing assisted reproductive technologies, particularly when utilizing donor eggs or donor sperm. Ensuring that the biological parents (or donors) do not carry matching genetic mutations is a vital quality control step in IVF. This screening ensures that the selected donor and the intended parent do not create a high-risk genetic combination, safeguarding the health of the future child.

What Does a VISTA Carrier Screening Test Detect?

The VISTA Carrier Screening Test at Chughtai Lab is designed to detect pathogenic variants, mutations, and structural alterations across hundreds of genes. Some of the primary conditions and genetic parameters evaluated include:

• Beta-Thalassemia (HBB Gene): Detects mutations responsible for reduced or absent beta-globin chain synthesis, preventing severe transfusion-dependent anemia in offspring.
• Alpha-Thalassemia (HBA1/HBA2 Genes): Identifies deletions or mutations that can lead to Hb H disease or fatal Hydrops Fetalis.
• Spinal Muscular Atrophy (SMN1 Gene): Screens for copy number deletions in the SMN1 gene, which cause progressive muscle wasting and motor neuron degeneration.
• Cystic Fibrosis (CFTR Gene): Identifies mutations in the CFTR gene that affect mucus production in the lungs and digestive system.
• Fragile X Syndrome (FMR1 Gene): Evaluates CGG trinucleotide repeat expansions associated with intellectual disability and autism spectrum disorders.
• Duchenne and Becker Muscular Dystrophies (DMD Gene): Detects deletions, duplications, and point mutations in the dystrophin gene causing progressive muscle weakness.
• Hemophilia A and B (F8 and F9 Genes): Screens for mutations causing coagulation factor deficiencies and bleeding disorders.
• Sickle Cell Anemia (HBB Gene): Identifies the specific Glu6Val mutation that causes red blood cells to assume an abnormal sickle shape.
• Tay-Sachs Disease (HEXA Gene): Detects mutations causing progressive neurodegeneration due to hexosaminidase A deficiency.
• G6PD Deficiency (G6PD Gene): Identifies variants predisposing individuals to hemolytic anemia under oxidative stress.
• Phenylketonuria (PAH Gene): Screens for mutations preventing the metabolism of phenylalanine, which can cause severe intellectual disability if untreated.
• Congenital Adrenal Hyperplasia (CYP21A2 Gene): Detects mutations affecting cortisol synthesis, leading to hormonal imbalances and atypical genitalia.
• Gaucher Disease (GBA Gene): Identifies lysosomal storage mutations leading to organomegaly and bone pain.
• Niemann-Pick Disease (SMPD1/NPC1/NPC2 Genes): Detects lipid storage mutations causing progressive neurological deterioration.
• Galactosemia (GALT Gene): Identifies mutations preventing the proper metabolism of galactose, leading to organ damage in infancy.
• Maple Syrup Urine Disease (BCKDHA/BCKDHB/DBT Genes): Screens for metabolic defects in branched-chain amino acid breakdown.
• Wilson Disease (ATP7B Gene): Identifies mutations leading to toxic copper accumulation in the liver and brain.
• Polycystic Kidney Disease, Autosomal Recessive (PKHD1 Gene): Detects mutations causing bilateral renal cysts and hepatic fibrosis in newborns.
• Alport Syndrome (COL4A3/COL4A4/COL4A5 Genes): Screens for collagen mutations leading to progressive renal failure and hearing loss.
• Glycogen Storage Diseases (Multiple Genes): Identifies enzymatic deficiencies affecting glycogen synthesis or breakdown.

Turnaround Time and Report Access at Chughtai Lab

Due to the highly complex nature of Next-Generation Sequencing, library preparation, and the intensive bioinformatics analysis required to interpret genomic data, the turnaround time for the VISTA Carrier Screening Test at Chughtai Lab is typically 3 to 4 weeks. Every genomic variant identified must be cross-referenced with international genetic databases (such as ClinVar and HGMD) and classified according to the American College of Medical Genetics and Genomics (ACMG) guidelines.

Once the clinical report is finalized and signed by a Consultant Molecular Pathologist, Chughtai Lab offers multiple convenient ways to access the results. Patients receive an automated SMS notification with a direct link to download their report. Reports can also be accessed online via the official Chughtai Lab website portal or through the Chughtai Lab Mobile App. For patients who prefer physical copies, reports can be collected from any of Chughtai Lab's numerous diagnostic centers nationwide, or delivered directly to their home through their dedicated report delivery service.

VISTA Carrier Screening Test Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
Autosomal Recessive Genes (e.g., HBB, CFTR, SMN1)	No pathogenic or likely pathogenic variants detected. Two functional copies of the gene present.	Heterozygous pathogenic variant detected (individual is a healthy carrier; 25% risk if partner is also a carrier).
X-Linked Genes in Females (e.g., DMD, F8)	No pathogenic mutations or premutations detected on either X chromosome.	Heterozygous pathogenic mutation detected (female is a carrier; 50% risk of passing condition to male offspring).
SMN1 Copy Number (SMA Screening)	Two or more copies of the SMN1 gene detected (low risk of being a carrier).	One copy of the SMN1 gene detected (confirmed carrier of Spinal Muscular Atrophy).
FMR1 CGG Repeat Count (Fragile X)	Fewer than 45 CGG repeats (normal range).	55 to 200 repeats (premutation carrier) or >200 repeats (full mutation).
Alpha-Globin Gene Deletions (HBA1/HBA2)	All four alpha-globin alleles intact (aa/aa).	One, two, or three allele deletions detected (carrier of alpha-thalassemia trait or Hb H disease).
Inborn Errors of Metabolism Panels	Normal enzymatic gene sequences; no pathogenic mutations identified.	Pathogenic variants detected in metabolic genes (e.g., PAH, GALT, GBA), indicating carrier status.
Variant Classification (ACMG Guidelines)	Benign or likely benign variants only (no clinical significance).	Pathogenic or Likely Pathogenic variants identified; Variants of Uncertain Significance (VUS) may require clinical correlation.

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient's symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Chughtai Lab for VISTA Carrier Screening?

• Experienced Healthcare Professionals: Chughtai Lab boasts a team of highly qualified consultant pathologists, molecular biologists, and genetic specialists who oversee all genomic testing.
• Patient-Focused Care: The lab prioritizes patient comfort, confidentiality, and clear communication throughout the genetic testing process.
• Quality Diagnostic Services: Chughtai Lab adheres to stringent international quality control standards, participating in external quality assurance programs to ensure maximum accuracy.
• Professional Reporting: Reports are structured in a clear, comprehensive, and clinically actionable format, adhering strictly to ACMG guidelines.
• Modern Diagnostic Approach: Utilizing state-of-the-art Next-Generation Sequencing (NGS) platforms ensures high analytical depth and coverage for genetic screening.
• Comfortable Environment: All Chughtai Lab collection centers nationwide are designed to provide a clean, professional, and welcoming experience for patients.
• Convenient Location: With hundreds of collection centers across Pakistan, patients can easily access testing services, submit samples, and consult with staff.
• Commitment to Accurate Diagnosis: Chughtai Lab is dedicated to delivering precise genetic insights, helping families make life-changing reproductive decisions with confidence.